It takes little imagination to see that the unborn Black baby is
the real object of many abortionists. Except for the privilege of
aborting herself, the Black woman and her family must fight for every
other social and economic privilege ... The quality of life for the
poor, Black, and the oppressed will not be served by destroying their
Erma Clardy Craven.
The United States has lagged far behind other nations for decades in
the field of birth control. With the introduction of the safe and
effective contraceptive NORPLANT, women will be able to protect
themselves from unwanted pregnancy for five years at a time.
No more will women have to interrupt their sexual foreplay to use
clumsy barrier methods, and no longer will they become pregnant when
they forget to take their birth control pills.
Abortion is a marvelously efficient weapon for the population
controllers, but it has its drawbacks. It is expensive, messy, and worst
of all it is being exposed as a racist institution by the very people
the abortionists accuse of being prejudiced.
For decades, the popcon fanatics have dreamed about a mass means of
neutering minority women that would be quick, efficient, and private.
And the concept of a "safe and handy" abortifacient is
certainly nothing new. A quarter-century ago, Garrett Hardin and other
population theorists fantasized that the dominant
"contraceptive" of the future would be an efficient
It appears that the science genie has finally granted the population
controller's wish. The United States Food and Drug Administration (FDA)
approved the abortifacient "contraceptive" NORPLANT for public
use on December 10, 1990.
The Power Behind the Plan.
The ominously-named Population Council (founded by population control
fanatic John Rockefeller III) owns the patent for NORPLANT, which was
developed by embryologist Sheldon Segal of the Rockefeller Foundation.
The Population Council will reap four percent of the colossal profits
that will accrue from the use of the drug. The abortifacient is produced
by Wyeth-Ayerst Laboratories of Philadelphia, a subsidiary of American
Home Products, and will cost women about $500 to produce about five
years of barrenness.
The Nuts and Bolts of
Implantation and Extraction Procedure.
The NORPLANT carrier consists of six small tubes about the size of
matchsticks. These tubes are made of silastic (silicone rubber), the
same material used in heart valves and medical tubing.
The insertion procedure is performed by a clinician, who makes a
1/8-inch incision about six inches above the woman's elbow. The capsules
are then loaded one by one into her arm in a fan-shaped pattern using an
insertion tube. Local anesthetic is used for both the implantation
and extraction procedures.
The removal of the six tubes will be tricker than implantation in
many cases, because they become coated with fibrous tissue and gradually
anchor into the surrounding tissue. This is a result of trauma caused by
the implants being pushed into the tissue and a low-scale inflammatory
reaction to the tube's foreign substance.
Mechanism of Action.
Once implanted, the six NORPLANT carrier capsules slowly release the
drug levonorgestrel (low-dosage progestin), an abortifacient that
prevents implantation of the developing human being (blastocyst) in the
The initial rate of progestin release is 100 micrograms per day. This
rate gradually declines to 30 micrograms per day after 27 months, and
then levels out.
One major study showed that NORPLANT may reduce but not inhibit sperm
migration by thickening cervical mucus, thus allowing fertilization to
take place. Another test of 41 women using NORPLANT for a period of
one year showed that 24 women experienced a suppressed uterine lining,
12 had an irregular uterine lining, and only five had normal (unchanged)
uterine linings. Thus, NORPLANT had a clearly abortifacient effect in
70 percent of the women tested.
This means that a woman being used by NORPLANT will continue to
ovulate, and will therefore be blissfully unaware that she is aborting
at least once or twice each year.
NORPLANT is a member of the single-synthetic hormone class of
abortifacients that include the 'mini-pill' and the Progestasert
intra-uterine device (IUD). These other abortifacients are described
in Chapters 31 and 32.
The manufacturers claim that the effectiveness rate of NORPLANT is
99.2 percent per year for women under 154 pounds and 98.3 percent per
year for women over 154 pounds.
NORPLANT Side Effects.
There is no question that NORPLANT users will experience a galaxy of
side effects ranging from the trivial to the extremely serious. These
impacts occur primarily in the first nine months of use, when the level
of hormone release from the capsules is highest, and when the woman's
body is being acclimatized to the drug.
According to Dr. John Hildebrand, the synthetic hormone in NORPLANT
"... louses up the lining of the uterus. It produces exhaustion of
the endometrium, depriving the lining of the uterus of the hormonal
support that it needs. [The drug] disturbs all factors in the blood
system. The drug is long-acting because the body can't digest these new
analogs. The body sees this as an abnormal thing and tries to get rid of
it. When it can't, it sets up violent reactions inside us. In the sense
that we are all different that our enzymes are as individual as our
fingerprints nobody can be certain of the effects this drug will
Although they naturally vary widely from woman to woman, the range
of typical NORPLANT side effects generally include;
changes in the endometrium (uterine lining);
odd menstrual bleeding patterns;
spotting between periods;
missed or prolonged periods;
sudden weight gain or loss;
increased hair loss or gain;
abnormal body hair growth;
high blood pressure;
'migration' of the six polymer capsules; and, ironically,
a decreased sex drive.
One study conducted in Singapore concluded that after one year of
use, women "... may have an increased predisposition to thrombosis
as evidenced by significant increase in platelet count and aggregability."
The results also show that NORPLANT acceptors may have an enhanced
potential for hypercoagulation ... "
Another study showed that there was a significant increase (58%) in
bilirubin in women who used NORPLANT for a year, indicating that the
abortifacient may cause serious liver dysfunction.
The United States Food and Drug Administration (FDA) has warned that
NORPLANT "... should not be used by women who have acute liver
disease, unexplained vaginal bleeding, breast cancer, or blood clots in
the legs, lungs, or eyes."
The Propaganda Machine Gears Up.
Groups that were already deeply involved in abortion, contraception,
and population control predictably downplayed the side effects of the
drug in their literature. The April 1990 issue of the International
Planned Parenthood Federation newsletter Medical Bulletin stated
that NORPLANT's most serious side effects were weight gain and a
"... greater risk that the pregnancy will be ectopic than if the
user were not using NORPLANT." The article failed to mention
impacts such as allergic/immune reactions or 'migration' of the six
The Dark Side of the
First South Africa, and Now ...
Many people, including Law Professor Charles Rice of Notre Dame
university, see a dark side to the great convenience of NORPLANT.
Certain countries, including South Africa, have made the injectable
abortifacient Depo-Provera mandatory for teenaged schoolgirls, female
prisoners, welfare recipients, and the mentally handicapped. And now,
radical thinkers are tentatively suggesting that NORPLANT be made
mandatory in certain cases for women in the United States (for more
information on how the United States ships dangerous birth-control
devices overseas in great quantities, see Chapter 131 in Volume III,
With so many influential people pushing abortion and birth control on
poor minority women, it is inevitable that the secret racist agenda will
slip out occasionally. Strangely, these stories seem to have little
effect on the blissfully unaware public. Typically, those pro-abortion
groups that claim to be fighting for the rights of minorities ignore
In a classic recent example, deputy editorial page editor Donald
Kimelman of the Philadelphia Enquirer stated in a December 12,
1990 article, chillingly entitled "Can Contraception Reduce the
Underclass?," that "As we read these two stories [about
NORPLANT and Black poverty], we asked ourselves: Dare we mention them in
the same breath? To do so might be considered deplorably insensitive,
perhaps raising the specter of eugenics. But it would be worse to avoid
drawing the logical conclusion that foolproof contraception could be
invaluable in breaking the cycle of inner city poverty one of America's
Kimelman went on to suggest that welfare mothers could be implanted
with NORPLANT for free and perhaps receive increased welfare benefits as
a reward. He apparently failed to realize that this was one of the first
elements of the coercive Chinese population program that now features
mandatory sterilization and forced abortions even in the ninth month of
Who is the Target?
We might ask ourselves this question: If Kimelman and his fellow
"thinkers" were truly concerned about poverty in general, why
do they not also recommend the use of NORPLANT for poor White
Others apparently asked this same question. Vanessa Williams,
president of the Philadelphia chapter of the National Association of
Black Journalists, called Kimelman's article "A tacit endorsement
of slow genocide."
Inquirer columnist Steve Lopez sarcastically suggested on December
16th that contraception would not reduce the underclass quite so fast as
"just shooting them."
The Philadelphia Enquirer publicly apologized for its racist
article on the 22nd of December, after a wave of complaints. But the
damage had been done; the racist thinking of the pro-abortionists and
some very influential people had been exposed once again.
Getting With the Program.
Immediately after NORPLANT was introduced to the public, several
judges ordered women (always poor Blacks) onto the drug because they had
been convicted of the abuse of previous children. In one such case,
Tulare County (California) Superior Court Judge Howard R. Broadman gave
Darlene Johnson a very simple but coercive choice: Be sterilized with
NORPLANT or go to jail for two to four years.
Nor did it take state legislatures long to perceive the dramatic
possibilities of using the drug. Kansas H.B. 2089 identified NORPLANT by
name in an act that would provide assistance to female welfare
recipients only if they agreed to be implanted.
NORPLANT and Third World
It is standard operating procedure (SOP) for contraceptive
manufacturers and population controllers to target Third World women
with new or untested abortifacient means of birth control. Additionally,
the old high-dose birth control pills and various IUDs that have proven
too dangerous for American women to use are shipped overseas by the tens
of millions, all in the name of population control.
At the turn of the century, the sun never set on the British empire.
If an empire could be defined as control of the wombs of poor women in
developing countries, there is a new empire upon which the sun never
sets the empire painstakingly constructed by the United States
Since the mid-1970s, the United States has been deeply committed to
both domestic and foreign population control programs. Billions of
dollars of our tax money have been used to implement many questionable
programs, including, most notably, the Chinese forced-abortion atrocity.
The National Security Council (NSC) is the highest U.S. bureaucracy
charged with the planning and direction of foreign policy. One of the
most vital aspects of this policy is population control.
One highly sensitive NSC document entitled "Implications of
Worldwide Population Growth for U.S. Security and Overseas
Interests" was written in 1974 and only declassified in late 1990.
This document served as the foundation for our country's anti-natalist
The document stated that "Commitment to population stabilization
will only take place when leaders of less-developed countries (LDCs)
clearly see the negative impact of unrestricted population growth and
believe it is possible to deal with this question through governmental
It suggested that United States food assistance might be made
conditional depending on the LDC's population control performance but
that "... it is important in style as well as substance to avoid
the appearance of coercion ... mandatory programs may be needed and that
we should be considering these possibilities now."
In 1976, the Interagency Task Force on Population Policy for the
Under Secretaries Committee of the NSC found that "In some cases,
strong direction has involved incentives such as payment to acceptors
for sterilization, or disincentives such as giving low priorities in the
allocation of housing and schooling to those with larger families. Such
direction is the sine-qua-non [essential essence] of an effective
The parallels to the U.S.-funded Chinese program (described in
Chapter 50, "Forced Abortions") are obvious.
Poor Women as Guinea Pigs.
NORPLANT was the final product of 24 years of Population Council
research. In 1990, The United States became the 17th country to accept
it for distribution. The abortifacient has been tested continuously
since 1972 on women in several developing countries by the United States
Agency for International Development (USAID), which provided most of the
$20 million in research costs.
At a 1990 meeting of the American Public Health Association (APHA),
Dr. Shayam Thapa claimed that, although doctors were eager to implant
the drug, only one-fourth of Bangladeshi women who wanted the capsules
removed could find a doctor to do so.
In 1990, the Hai News, a Korean newspaper, reported that a
health advocacy group in Bangladesh called UBINIG had uncovered
"gross violations of medical ethics" regarding distribution of
NORPLANT. Korean women were not informed that the drug was
experimental and were not told of any side effects. Many women were
bribed to use the drug, and were instructed not to report side effects
so that the test program results would be skewed to "show"
lower rates of health problems. When women became too sick to avoid
seeking medical attention, proper care was withheld from them.
 Erma Clardy Craven, quoted in "Abortion, Poverty, and Black
Genocide." T.W. Hilgers and D.J. Horan (editors). Abortion and
Social Justice. New York: Sheed and Ward, 1972.
 Garrett Hardin. "The History and Future of Birth
Control." Perspectives in Biology and Medicine, Autumn 1966.
 Paul Likoudis. "Five-Year Birth Control Device Approved By
FDA." The Wanderer, December 20, 1990, pages 3 and 12.
 Dale N. Robertson. "Implantable Levonorgestrel Rod Systems: In
Vivo Release Rates and Clinical Effects." Also see Horacio B.
Croxatto, et al. "Histopathology of the Endometrium During
Continuous Use of Levonorgestrel." Both included in Gerald I.
Zatuchini (editor). Long Acting Contraceptive Delivery Systems.
New York: Harper & Row, 1984. Pages 133 to 144 and 290 to 295,
 Robert A. Hatcher, et al. Contraceptive Technology:
1988-1989, 14th Revised Edition. New York: Irvington Publishers,
1988. Pages 251 and 252.
 O.A.C. Viegas, et al. "The Effects of NORPLANT on
Clinical Chemistry in Singaporean Acceptors After 1 Year of Use:
Haemostatic Changes." Contraception, September 1988, Volume
38, Number 3. Pages 313 to 323.
 O.A.C. Viegas, et al. "The Effects of NORPLANT on
Clinical Chemistry in Singaporean Acceptors After 1 Year of Use:
Metabolic Changes." Contraception, September 1988, Volume
38, Number 1. Pages 79 to 89.
 Don Kimelman. "Poverty and NORPLANT: Can Contraception
Reduce the Underclass?" Philadelphia Enquirer, December 12,
 Clarence Page. "Hope Best Way to Fight Poverty." The
Oregonian, December 31, 1990, page C5.
 Joe Bigham. "Birth Control Order Stands Until Appeal."
The Oregonian, January 11, 1991, page A16.
 "Chemical Warfare." Communique, March 1, 1991,
page 1. Publication of American Life League.
 Elizabeth Sobo. "NORPLANT: Lab-Tested on Third World
Women." Our Sunday Visitor, February 3, 1991, pages 10 and
Further Reading: NORPLANT.
Nona Aguilar. No-Pill, No-Risk Birth Control.
New York: Rawson, Wade Publishers, 1980. 235 pages; paperback,
hardback. Reviewed by Edward F. Keefe in the Spring 1980 issue of the International
Review of Natural Family Planning, pages 81 to 84, and by Rose
Fuller on pages 177 to 179 of the Summer 1986 issue of the same
publication. This book extols the virtues of natural family planning
while explaining the "shocks" to the system of sterilization
and the various methods of artificial contraception. A good 'theory'
American Society of Law & Medicine. Antiprogestin Drugs:
Ethical, Legal and Medical Issues.
Proceedings from the conference at the Hyatt Regency Crystal City,
Arlington, Virginia, December 6-7, 1991. 1992, 589 pages. Order from the
American Society of Law & Medicine, 765 Commonwealth Avenue, Boston,
Massachusetts 02215. A series of fifty papers on all aspects of use and
impacts of the abortion pill RU-486 and the insertable abortifacient
NORPLANT. The ethics and implementation of these drugs and of early
abortion and contraception in developing nations is also covered in
detail by some of the world's leading pro-abortion strategists.
Human Life International. Project Abortifacients.
June 1991, 23 pages. This summary report, updated periodically by
Human Life International, lists major quotes and many major studies on
the abortifacient mode of action and side effects of the most common
abortifacients: The birth control pill, the intra-uterine device (IUD),
NORPLANT, RU-486, and Depo-Provera. Available from Human Life
International, 7845-E Airpark Road, Gaithersburg, Maryland 20879.
United States Government, Food and Drug Administration. Requirements
of Laws and Regulations Enforced by the United States Food and Drug
This publication is intended to be a cross reference to the major
requirements of laws and regulations administered by the FDA. This book
could come in handy for pro-lifers trying to track the distribution of
new IUDs, NORPLANT, and the resurgence of the use of Depo-Provera by
poor women. Serial Number 017-012-00343-5, 1989, 85 pages. Order by mail
from Superintendent of Documents, United States Government Printing
Office, Washington, DC 20402, or by telephone from (202) 783-3238.
Brian Young, J.D. "Fact Sheet: New 'Under the Skin'
Abortifacient Birth Control Drug/Device Implant."
1990, 8 page booklet on NORPLANT. Order from American Life League,
Post Office Box 490, Stafford, Virginia 22554. Telephone: (703)
© American Life League BBS 1-703-659-7111
This is a chapter of the Pro-Life Activist's Encyclopedia,
published by American Life League.